BMY Stock Chart & Fundamental Analysis

Interactive Chart

About Bristol-Myers Squibb Company

Name

Bristol-Myers Squibb Company

CEO

Christopher S. Boerner

Website

www.bms.com

Industry

Healthcare

Year Founded

1933

Employees

34,100

Bristol-Myers Squibb Company is a biopharmaceutical enterprise that discovers, develops, and commercializes medicines in oncology, immunology, cardiovascular disease, and other therapeutic areas. Research programs span biologics and small molecules guided by translational science, clinical development, and collaborations with academic groups and biotechnology partners. Manufacturing and quality systems support global supply for hospitals and pharmacies, while medical affairs and patient services help clinicians use therapies appropriately. The company engages regulators and health systems across North America, Europe, and key international markets, aligning access strategies with local standards of care. Within the healthcare ecosystem, Bristol-Myers Squibb contributes targeted treatments and pursues pipelines intended to address complex, chronic conditions.

Analyst Ratings

Consensus Recommendation

Buy10

Hold7

Sell4

Fundamentals & Financials

Revenue (TTM)

$48.1B

Net Income (TTM)

$7B

EPS (TTM)

$3.46

ROA (TTM)

66.08%

Current Ratio

-4.72

Dividend Yield

0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q4 2025	Q3 2025	Q2 2025
Revenue	$12,502M	$12,222M	$12,269M
Cost of Sales	$4,097M	$3,435M	$4,199M
Gross Profit	$8,405M	$8,787M	$8,070M
Operating Income	$1,419M	$3,639M	$4,117M
Net Income	$1,086M	$2,201M	$1,310M
EPS	$0.53	$1.08	$0.64

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Bristol-Myers Squibb Company's Technical Indicators Summary

BMY is currently exhibiting a neutral technical profile, with momentum indicators like the RSI and CCI suggesting a cautious hold, while the Stochastic oscillator signals some short-term selling pressure. The ADX points to a moderately strong trend, supported by price remaining above key medium- and long-term moving averages, despite short-term averages indicating slight weakness. Volatility remains steady, as reflected by the average true range, and volume trends show some divergence with the on-balance volume suggesting selling interest. Overall, the technical landscape reflects a balance between bullish and bearish forces, resulting in a neutral stance. The current setup indicates consolidation rather than clear directional bias.

Buy

10 signals

Neutral

7 signals

Sell

4 signals

Overall: Neutral33% Neutral signals

Indicator	Value	Signal	Explanation
RSI (14)	56.86	Neutral	RSI (56.86) is neutral.
Stochastic %K (14, 3, 3)	85.14	Sell	Stochastic (85.14) > 80, indicating overbought.
CCI (20)	51.52	Neutral	CCI (51.52) is neutral.
WPR (14)	-35.74	Neutral	Williams %R (-35.74) is neutral.
Momentum (10)	1.80	Buy	Momentum (1.80) is positive.
MFI	43.63	Neutral	MFI (43.63) is neutral.
MACD Level (12, 26)	1.31	Neutral	Potential bearish reversal: MACD (1.31) crossed below signal but is still positive.
Bollinger Bands	$52.57 - $57.24	Neutral	Price is within the bands.
ATR (14)	$1.22 (2.20%)	Neutral	Moderate Volatility (2.20%).
ADX (14)	35.92	Buy	Strong uptrend (ADX > 25) with bullish directional movement. ADX(35.92), +DI(27.07), -DI(14.39)
OBV	168,878,700	Sell	Bearish volume pressure: OBV is below its 20-day SMA. OBV(168,878,700), 20D-SMA-OBV(189,333,360)
Simple Moving Averages	$48.31 - $55.65(5 indicators)	Buy	The price is slightly below the short-term 10-period SMA but remains above the 20-, 50-, 100-, and 200-period SMAs, indicating a predominantly bullish trend with minor short-term weakness.
Exponential Moving Averages	$50.34 - $55.64(5 indicators)	Buy	The price is below the short-term 10-period EMA but remains above the 20-, 50-, 100-, and 200-period EMAs, indicating a mixed short-term signal within an overall bullish trend.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the bell, BMY was still trading below yesterday, reflecting a -0.609% opening gap down and a close near 60.37. End-of-day derivatives positioning for BMY stayed heavily call-biased, with PCR at a very low 0.47. BMY's stock declines amid limited headlines despite FDA acceptance of iberdomide NDA and strong derivatives positioning.

Price Change

from $60.74 close

-$0.37

Trading Volume

Below avg (14.6M)

9.2M

vs S&P 500 Today

Underperforming Market

-0.52%

52-Week Position

Upper range

85.8%